Sylke Maas | VP, IR and Business Strategy |
Ugur Sahin | Co-Founder & CEO |
Ozlem Tureci | Co-Founder & Chief Medical Officer |
Jens Holstein | CFO |
Ryan Richardson | Chief Strategy Officer |
Matthew Harrison | Morgan Stanley |
Cory Kasimov | JPMorgan Chase & Co. |
Christopher Zopf | Goldman Sachs Group |
Akash Tewari | Jefferies |
Zhiqiang Shu | Berenberg |
Daina Graybosch | SVB Leerink |
Welcome to the BioNTech First Quarter 2022 Update Call. I would like to hand the call over to the Vice President of Investor Relations and Strategy, Sylke Maas. Please go ahead, Sylke.
Good morning and good afternoon, and thank you for joining us today to review BioNTech's first quarter 2022 clinical and operational and financial results. A few housekeeping items before we start.